FDA Vaccine Chief Dr. Vinay Prasad Exiting Role

Follow Drugslib on

By HealthDay Staff HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on March 9, 2026.

via HealthDay

MONDAY, March 9, 2026 — Dr. Vinay Prasad, who leads the U.S. Food and Drug Administration (FDA) division that oversees vaccines and complex medical treatments, is leaving the agency at the end of April.

Prasad took on the job last May but faced criticism during his short stint.

FDA Commissioner Dr. Marty Makary said Prasad will return to the University of California at San Francisco, where he is a professor.

“He got a tremendous amount accomplished within his one-year sabbatical … and will be returning back to his academic home later next month,” Makary wrote in a post on X.

Makary also highlighted work Prasad helped lead, including new rules limiting approvals of updated COVID-19 vaccines mainly to older adults and people with health problems and a voucher program meant to speed up certain drug decisions.

Prasad’s stint has been marked by political battles and disagreements over drug and vaccine policy.

Last July, he was briefly dismissed at the White House’s direction after pressure from critics over his handling of drug approvals and his past support for Democrats.

Prasad returned less than two weeks later after Makary asked the White House to reconsider.

Later last year, Prasad suggested stricter federal guidelines for vaccine approvals. He said his team had concluded that COVID vaccines might have caused the deaths of at least 10 children, though he did not provide evidence.

Some former FDA leaders warned the changes could weaken the nation’s response to infectious diseases.

“I remain open to vigorous discussions and debate,” Prasad wrote in an internal email to staff at the time, The Washington Post reported.

He also told employees who strongly disagreed with the direction that they should consider resigning.

Prasad also faced criticism over several other decisions.

A recent conflict involved Moderna, after the FDA declined to review the company’s application for what could become the first mRNA-based flu vaccine. The agency backtracked a week later and agreed to review the submission.

Another disagreement involved a possible treatment for Huntington’s disease being developed by gene therapy company uniQure, with disagreements about how the clinical study should be designed.

Before joining the federal government, Prasad worked as a hematologist and oncologist and taught at UC-San Francisco.

He gained attention for criticizing how some cancer drugs are approved and questioning several pandemic-era policies.

The FDA is now searching for someone new to lead the agency’s Center for Biologics Evaluation and Research, according to an internal email obtained by The Post.

Prasad had assumed that role after Dr. Peter Marks, a key figure in the rapid development of COVID-19 vaccines, was forced out by the Trump administration.

Prasad’s departure dovetails with major leadership changes across the U.S. Department of Health and Human Services, as officials work to stabilize an agency known to have faced internal conflicts.

Sources

  • The Washington Post, March 6, 2026

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-03-10 01:46

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords